{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T14:35:25Z","timestamp":1793025325456,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100022752","name":"MSD Sharp & Dohme GmbH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022752","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100024580","name":"Orion Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024580","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme United Kingdom","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ejca.2026.117041","type":"journal-article","created":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T06:47:30Z","timestamp":1789195650000},"page":"117041","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Steroidogenesis inhibitor ODM-209 for metastatic castration-resistant prostate cancer and advanced breast cancer: Results from the first-in-human STESIDES study"],"prefix":"10.1016","volume":"248","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9706-3945","authenticated-orcid":false,"given":"Alice","family":"Bernard-Tessier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iben","family":"Spanggaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tapio","family":"Utriainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minna","family":"Tanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristoffer","family":"Rohrberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natacha","family":"Naoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2018-6370","authenticated-orcid":false,"given":"Tarja","family":"Ikonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0689-2764","authenticated-orcid":false,"given":"Pasi","family":"Pohjanjousi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2137-1017","authenticated-orcid":false,"given":"Chris","family":"Garratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3348-3059","authenticated-orcid":false,"given":"Christian","family":"Poehlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Fizazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2026.117041_bib1","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","article-title":"5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)","volume":"31","author":"Cardoso","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.117041_bib2","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41391-018-0079-0","article-title":"Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations","volume":"22","author":"Crawford","year":"2019","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.ejca.2026.117041_bib3","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/j.1742-1241.2011.02799.x","article-title":"Characterising the castration-resistant prostate cancer population: a systematic review","volume":"65","author":"Kirby","year":"2011","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.ejca.2026.117041_bib4","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.117041_bib5","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.117041_bib6","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2\u2009\u00d7\u20092 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2026.117041_bib7","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.117041_bib8","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2026.117041_bib9","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1146\/annurev-med-051517-011947","article-title":"Treatment of advanced prostate cancer","volume":"70","author":"Teo","year":"2019","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.ejca.2026.117041_bib10","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","article-title":"EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II 2020 update: treatment of relapsing and metastatic prostate cancer","volume":"79","author":"Cornford","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejca.2026.117041_bib11","doi-asserted-by":"crossref","DOI":"10.5489\/cuaj.8161","article-title":"2022 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: management of castration-resistant prostate cancer (CRPC)","volume":"16","author":"Saad","year":"2022","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.ejca.2026.117041_bib12","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.annonc.2023.02.015","article-title":"Updated treatment recommendations for prostate cancer from the ESMO Clinical Practice Guideline considering treatment intensification and use of novel systemic agents","volume":"34","author":"Fizazi","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.117041_bib13","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ejca.2023.02.018","article-title":"Management of patients with advanced prostate cancer: Report from the Advanced Prostate Cancer Consensus Conference (APCCC) 2022","volume":"185","author":"Gillessen","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.117041_bib14","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.eururo.2024.09.017","article-title":"Management of patients with advanced prostate cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)","volume":"87","author":"Gillessen","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejca.2026.117041_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2023.100962","article-title":"Current therapy and drug resistance in metastatic castration-resistant prostate cancer","volume":"68","author":"Cai","year":"2023","journal-title":"Drug Resist Updat"},{"issue":"8","key":"10.1016\/j.ejca.2026.117041_bib16","doi-asserted-by":"crossref","DOI":"10.1200\/PO.23.00330","article-title":"Prevalence and spectrum of AR ligand-binding domain mutations detected in circulating-tumor DNA across disease states in men with metastatic castration-resistant prostate cancer","author":"Antonarakis","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ejca.2026.117041_bib17","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1200\/JCO.2023.41.6_suppl.221","article-title":"Androgen receptor (AR) mutations in men with metastatic castration-resistant prostate cancer (mCRPC): incidence and natural history","volume":"41","author":"Bernard-Tessier","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.117041_bib18","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-16-0422","article-title":"Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence","volume":"23","author":"Coutinho","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ejca.2026.117041_bib19","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1055\/a-2238-3199","article-title":"Identification of patients with early HR+ HER2- breast cancer at high risk of recurrence","volume":"84","author":"Fasching","year":"2024","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"10.1016\/j.ejca.2026.117041_bib20","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1200\/JCO.22.00519","article-title":"Systemic therapy for advanced human epidermal growth factor receptor 2-positive breast cancer: ASCO guideline update","volume":"40","author":"Giordano","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.117041_bib21","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"35","author":"Loibl","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2026.117041_bib22","first-page":"413","article-title":"Hormone therapy in breast cancer","volume":"112","author":"Dr\u0103g\u0103nescu","year":"2017","journal-title":"Chir (Bucur)"},{"key":"10.1016\/j.ejca.2026.117041_bib23","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1159\/000508675","article-title":"Endocrine-resistant breast cancer: mechanisms and treatment","volume":"15","author":"Hartkopf","year":"2020","journal-title":"Breast Care (Basel)"},{"key":"10.1016\/j.ejca.2026.117041_bib24","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41568-023-00604-3","article-title":"Therapeutic resistance to anti-oestrogen therapy in breast cancer","volume":"23","author":"Will","year":"2023","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ejca.2026.117041_bib25","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1210\/er.2010-0013","article-title":"The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders","volume":"32","author":"Miller","year":"2011","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ejca.2026.117041_bib26","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1158\/1535-7163.MCT-22-0115","article-title":"First-in-class small molecule to inhibit CYP11A1 and steroid hormone biosynthesis","volume":"21","author":"Karimaa","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ejca.2026.117041_bib27","article-title":"Targeted inhibition of CYP11A1 in castration-resistant prostate cancer","volume":"3","author":"Fizazi","year":"2024","journal-title":"NEJM Evid"},{"key":"10.1016\/j.ejca.2026.117041_bib28","unstructured":"U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 Published: November 27, 2017. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf. Accessed 27 May 2025."},{"key":"10.1016\/j.ejca.2026.117041_bib29","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ejca.2016.03.082","article-title":"RECIST 1.1 - standardisation and disease-specific adaptations: perspectives from the RECIST Working Group","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2026.117041_bib30","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.117041_bib31","doi-asserted-by":"crossref","first-page":"C2","DOI":"10.1093\/eurheartj\/suaa004","article-title":"Pharmacological cancer treatment and venous thromboembolism risk","volume":"22","author":"Mu\u00f1oz Mart\u00edn","year":"2020","journal-title":"Eur Heart J Suppl"},{"key":"10.1016\/j.ejca.2026.117041_bib32","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jamainternmed.2013.122","article-title":"Use of glucocorticoids and risk of venous thromboembolism: a nationwide population-based case-control study","volume":"173","author":"Johannesdottir","year":"2013","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.ejca.2026.117041_bib33","doi-asserted-by":"crossref","first-page":"TPS5113","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS5113","article-title":"CYP11A1 inhibitor MK-5684 versus next-generation hormonal agent (NHA) switch in patients with metastatic castration-resistant prostate cancer (mCRPC) after NHA and taxane-based chemotherapy: phase 3 MK-5684-003 trial","volume":"42","author":"Yu","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2026.117041_bib34","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41392-022-01042-7","article-title":"Targeting signaling pathways in prostate cancer: mechanisms and clinical trials","volume":"7","author":"He","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.ejca.2026.117041_bib35","doi-asserted-by":"crossref","first-page":"R143","DOI":"10.1530\/ERC-22-0140","article-title":"Androgen receptor mutations for precision medicine in prostate cancer","volume":"29","author":"Shiota","year":"2022","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.ejca.2026.117041_bib36","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13058-021-01462-3","article-title":"ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer","volume":"23","author":"Brett","year":"2021","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ejca.2026.117041_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2022.188830","article-title":"ESR1 activating mutations: from structure to clinical application","volume":"1878","author":"Grinshpun","year":"2023","journal-title":"Biochimica et Biophysica Acta (BBA) - Reviews Cancer"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926008221?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804926008221?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T13:52:02Z","timestamp":1793022722000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804926008221"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":37,"alternative-id":["S0959804926008221"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2026.117041","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Steroidogenesis inhibitor ODM-209 for metastatic castration-resistant prostate cancer and advanced breast cancer: Results from the first-in-human STESIDES study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2026.117041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s) and Merck & Co., Inc., Rahway, NJ, USA and its affiliates. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117041"}}